(Q37988905)

26 August 2017

title

Therapy innovation for the treatment of pancreatic neuroendocrine tumors (English)

1 reference

26 August 2017

Ferdinando Riccardi

1

1 reference

26 August 2017

Mimma Rizzo

2

1 reference

26 August 2017

Lucia Festino

3

1 reference

26 August 2017

Francesca Ambrosio

4

1 reference

26 August 2017

Carlo Molino

5

1 reference

26 August 2017

Generoso Uomo

6

1 reference

26 August 2017

Giacomo Cartenì

7

1 reference

26 August 2017

language of work or name

English

0 references

publication date

29 February 2012

1 reference

Expert Opinion on Therapeutic Targets

26 August 2017

published in

1 reference

26 August 2017

volume

16 Suppl 2

1 reference

26 August 2017

page(s)

S91-102

1 reference

Population-based study of islet cell carcinoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Small intestinal neuroendocrine cell pathobiology: 'carcinoid' tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Pax genes in embryogenesis and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Angiogenesis in endocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Antiangiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Endothelial-pericyte interactions in angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

PDGF receptors as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Glycemic control in patients with insulinoma treated with everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

New treatment options for patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Current knowledge on diagnosis and staging of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Pancreatic Endocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.665880

10.1517/14728222.2012.665880

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference